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Abstract
Experimental evidence indicates that small concentrations of inflammatory molecules produced by damaged tissues activate afferent signals through ascending vagus nerve fibers, that act as the sensory arm of an “inflammatory reflex”. The subsequent activation 
of vagal efferent fibers, which represent the motor arm of the inflammatory reflex, rapidly leads 
to acetylcholine release in organs of the reticuloendothelial system. Acetylcholine interacts with 
a7 subunit‑containing nicotinic receptors in tissue macrophages and other immune cells and 
rapidly inhibits the synthesis/release of tumor necrosis factor‑a and other inflammatory cytok‑
ines. This neural anti‑inflammatory response called “cholinergic anti‑inflammatory pathway” is 
fast and integrated through the central nervous system. Preclinical studies are in progress, with 
the aim to develop therapeutic agents able to activate the cholinergic anti‑inflammatory pathway. 
Melanocortin peptides bearing the adrenocorticotropin/a‑melanocyte‑stimulating hormone 
sequences exert a protective and life‑saving effect in animals and humans in conditions of circula‑
tory shock. These neuropeptides are likewise protective in other severe hypoxic conditions, such as 
prolonged respiratory arrest, myocardial ischemia, renal ischemia and ischemic stroke, as well as in 
experimental heart transplantation. Moreover, experimental evidence indicates that melanocortins 
reverse circulatory shock, prevent myocardial ischemia/reperfusion damage and exert neuropro‑
tection against ischemic stroke through activation of the cholinergic anti‑inflammatory pathway. 
This action occurs via stimulation of brain melanocortin MC3/MC4 receptors. Investigations that 
determine the molecular mechanisms of the cholinergic anti‑inflammatory pathway activation 
could help design of superselective activators of this pathway.
Introduction
Melanocortins have long been considered to only exert control on endocrine and pigmentary 
processes. For the first time our Teacher, Professor William Ferrari, in 1955,1‑3 then Professor 
David De Wied4 and over the subsequent decades several other independent groups, reported 
many important extra‑hormonal effects of melanocortins.5‑10 In addition to the pituitary gland, 
production of melanocortins was also documented in a variety of peripheral tissues and within the 
central nervous system (CNS).5,9,11 Altered production of these neuropeptides has been recognized 
among the causes of many morbid conditions including anorexia, hyperfagia, obesity, cachexia, 
pain, inflammation, sexual dysfunctions, circulatory shock, organ damage induced by ischemia/
reperfusion, neurodegeneration.5,7,9‑13 a‑Melanocyte‑stimulating hormone (a‑MSH) is the natural 
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melanocortin peptide able to induce all extra‑hormonal effects of melanocortins. Identification and 
cloning of the five melanocortin receptors (MC1‑MC5) in the nineties,14‑21 as well as the synthesis 
of selective agonists and antagonists at MC receptors,13,16,21 increased the general interest for this 
family of molecules in view of their possible therapeutic use.5,7,11,13,22‑25
The protective and resuscitating effects of melanocortins in extreme hypoxic condition ap‑
pear particularly promising for therapeutic purposes. Adrenocorticotropin (ACTH)/a‑MSH 
sequences, as well as shorter fragments and synthetic analogs, have a life‑saving effect in animals 
and humans in conditions of circulatory shock.26‑34 These neuropeptides are likewise protective in 
other severe hypoxic conditions, including prolonged respiratory arrest,35 myocardial ischemia,36‑41 
renal ischemia42‑44 and ischemic stroke,45‑49 as well as in experimental heart transplantation.50
Preclinical evidence indicates that melanocortins produce their protective and life‑saving effects, 
at least in part, by activating the recently recognized “cholinergic anti‑inflammatory pathway”, the 
motor arm of the “inflammatory reflex”.51‑53
The Inflammatory Reflex
In the past, the vagus nerve was only considered a part of the parasympathetic nervous system 
with precise functions, such as the regulation of heart and gut activities and respiration. However, 
more recent data have disclosed previously unrecognized functions of the vagus nerve. Electrical 
stimulation of the vagus nerve is currently approved for treatment of epilepsy and major depression; 
additional therapeutic uses under investigations include obesity, Alzheimer’s disease, chronic pain 
and some neuropsychiatric disorders.54,55 The mechanisms underlying the beneficial effects of the 
vagus nerve therapy are not fully understood.
The CNS modulates local and systemic inflammatory responses to various stressor agents 
through humoral and neural mechanisms.56‑58 High levels of cytokines and other inflammatory 
mediators can reach brain areas devoid of blood‑brain barrier (dorsal vagal complex including 
the sensory nuclei of the solitary tract, area postrema and dorsal motor nucleus of the vagus).59‑61 
This humoral route for communication between the immune system and the CNS seems to be 
involved in several processes, including fever, anorexia and activation of hypothalamic‑pituitary 
responses. Knowledge of the humoral route was the base for development of anti‑inflammatory 
drugs including glucocorticoids.52,62‑64
Efferent vagus nerve signalling contributes to modulation of inflammation. Efferent vagal 
signalling may facilitate lymphocyte release from the thymus through a nicotinic acetylcholine 
receptor‑mediated mechanism; moreover, clinical studies indicate that nicotine exerts beneficial 
influences in inflammatory bowel disease.52 These observations led Tracey and coworkers to hy‑
pothesize that the parasympathetic nervous system could modulate the systemic inflammatory 
response, as an alternative mechanism for rapid cytokine control. They verified this hypothesis in 
experimental models of endotoxic shock in rats and their investigations led to the identification of 
the “cholinergic anti‑inflammatory pathway”, the motor arm of the “inflammatory reflex”.51 Low 
levels of inflammatory molecules produced in damaged tissues activate afferent signals through 
ascending vagus nerve fibers (neural inflammation‑sensing pathways at low threshold of detection) 
and this could serve as the sensory arm of the inflammatory reflex.52,62‑64 The subsequent activa‑
tion of vagus efferent activity, which includes the motor arm of the inflammatory reflex, rapidly 
leads to acetylcholine release in organs of the reticuloendothelial system (liver, lung, heart, spleen, 
kidney and gastrointestinal tract). Acetylcholine interacts with a7 subunit‑containing nicotinic 
acetylcholine receptors in tissue macrophages and other immune cells surrounding the cholinergic 
terminals and rapidly inhibits synthesis/release of tumor necrosis factor‑a (TNF‑a), interleukin‑1 
(IL‑1) and other cytokines: this neural anti‑inflammatory response is fast and integrated within 
the CNS.51‑53,65 The old observations by Guarini and coworkers,66,67 that nicotine and dimethylphe‑
nylpiperazinium reverse hemorrhagic shock through a peripheral, nicotinic receptor‑mediated 
mechanism, can be explained on the basis of these novel findings.
Based on the observations by Tracey and coworkers, our group identified the cholinergic 
anti‑inflammatory pathway in hemorrhage‑shocked rats.65 Subsequently, several other groups 
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have shown the activity of this cholinergic anti‑inflammatory pathway in various experimental 
conditions characterized by a systemic inflammatory response.52,53,68‑71 Preclinical studies are in 
progress to verify the role of the cholinergic anti‑inflammatory pathway in local and systemic 
experimental diseases. Indeed, activation of this pathway could be used therapeutically. Vagus 
nerve control of visceral organs is integrated and regulated through the CNS. Reciprocal neural 
interconnections among the nucleus tractus solitarius, dorsal motor nucleus of the vagus, nucleus 
ambiguus, other forebrain structures such as hypothalamus, amygdala and insular cortex, form a 
brain network that regulates efferent vagal activity and related visceral organ functions.72 Receptors 
belonging to this central autonomic network could be targets for activators of the cholinergic 
anti‑inflammatory pathway.
Antishock Effects of Melanocortins
Circulatory shock is a severe pathological condition accompanied by a systemic inflammatory 
response, with upregulated expression of inflammatory mediators and recruitment of inflamma‑
tory cells in several tissues. Activation of nuclear transcription factors including NF‑kB triggers an 
inflammatory cascade with production of cytokines, such as TNF‑a, chemokines, cell adhesion 
molecules, free radicals including nitric oxide and other inflammatory mediators.31,32,34,51‑53,65,73‑77 
The multiple organ injury that is often associated with shock can be caused by both hypoperfusion 
and reperfusion during resuscitation.73,78‑80
The antishock effects of melanocortin peptides ACTH‑(4‑10), a‑MSH, ACTH‑(1‑17), 
ACTH‑(1‑24), discovered in our laboratory, has been subsequently confirmed in several studies. 
The original investigations were performed in a severe model of hemorrhagic shock, induced by 
stepwise withdrawal of about 50% of the circulating blood in rats and dogs. This procedure causes 
death in all animals within 30‑35 min.26,27,81‑83 Conversely, intravenous injection of melanocortin 
peptides rapidly induces a dose‑dependent restoration of arterial blood pressure and tissue blood 
flow. Normalization of arterial and venous pH and base excess, as well as of venous tension of O2 
and CO2 and of venous oxygen saturation and lactate, also gradually occur.84 The reversal of hemor‑
rhagic shock induced by melanocortin peptides is associated with marked increase in circulating 
blood volume. Such increase is the consequence of mobilization of the peripherally pooled residual 
blood from the liver, spleen and other organs.28,83,85 Subsequent studies using the same experimental 
model indicated that melanocortins greatly prolong survival and extend the time‑limit for effec‑
tive blood reinfusion (up to 3‑4 hours after shock, versus 10‑15 min in saline‑treated animals) for 
complete shock reversal.29
These resuscitating effects have been confirmed in the same animal models of hemorrhagic 
shock,86 as well as in hemorrhage‑shocked/resuscitated hamsters,87 in hypovolemic shock induced 
in rabbits by graded occlusion of the inferior vena cava,88 in a rat model of splanchnic artery oc‑
clusion34 and in a severe model of prolonged respiratory arrest in rats.35 ACTH‑(1‑24) has then 
been successfully used in human conditions of hemorrhagic and cardiogenic shock (intravenous 
bolus of 5‑10 mg), both in anecdotal cases and randomized controlled studies.33,89‑92
Clinical studies on the effectiveness of melanocortins in circulatory shock are in progress. 
From a practical point of view, availability of drugs able to retard shock progression toward an 
irreversible state, extending the time‑limit for a successful first aid of civilian and military victims 
of traumatic accidents, is of great importance.
The antishock effects of melanocortins are adrenal‑independent, can be obtained with intrac‑
erebroventricular injection of doses much lower than those required by the intravenous route 
and are mediated by melanocortin MC4 receptors located in the CNS.26,30,32,82 Such effects are 
associated with marked reduction in NF‑kB activation and plasma concentrations of inflam‑
matory mediators, including TNF‑a, oxygen free radicals and nitric oxide and in intercellular 
adhesion molecule expression by vascular endothelium.31,34,75,76,93 This action is consistent with the 
established anti‑inflammatory influence of melanocortins7,11 and suggests that the ability of these 
neuropeptides to extend the time‑limit for an effective blood reinfusion29 may be due to blockade 
of the mechanisms responsible for late organ failure and death.
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The antishock effect of melanocortins is prevented by a) bilateral cervical vagotomy, b) the 
intracerebroventricular injection of the acetylcholine‑depleting agent hemicholinium‑3 and c) the 
pharmacological blockade of central (but not peripheral) muscarinic acetylcholine receptors.94,95 
These observations suggest a contribution by CNS cholinergic pathways involving muscarinic 
receptors. Indeed, cholinomimetic agents, able to cross the blood‑brain barrier, likewise reverse 
hemorrhagic shock, in rats and rabbits.96‑98
The impressive resuscitating effect of melanocortins in severe shock models, the ineffectiveness 
of the conventional antishock drugs in the same animal models,99 as well as the beneficial results 
obtained in human conditions of hemorrhagic and cardiogenic shock, suggest that melanocortins 
acting at MC4 receptors could be innovative and promising resuscitating drugs in conditions of 
circulatory shock.
Melanocortins Reverse Circulatory Shock through Activation 
of the Cholinergic Anti‑Inflammatory Pathway
Efferent vagus nerve signalling reduces the systemic inflammatory response in endotoxic 
shock. Indeed, electrical stimulation of efferent vagal fibers during experimental letal endotoxemia 
blunts hepatic TNF‑a synthesis/release, attenuates serum levels of this cytokine and prevents 
shock development.51 Moreover, acetylcholine reduces release of several inflammatory cytokines 
by lipopolysaccharide‑stimulated human macrophages and this effect is counteracted by nicotinic 
receptor antagonists. In hemorrhagic shock, as well as in splanchnic artery occlusion shock, elec‑
trical stimulation of efferent vagal fibers rapidly reverses hypotension, prevents hepatic NF‑kB 
activation, blunts hepatic TNF‑a synthesis/release, lowers TNF‑a serum levels and improves 
survival in rats.65,77 These findings suggest that a “cholinergic anti‑inflammatory pathway” oper‑
ates during endotoxic, hemorrhagic and splanchnic artery occlusion shock, to counterbalance 
development of the inflammatory cascade responsible for vascular derangement and multiple 
organ failure (Fig. 1). Identification of drugs able to activate this pathway might provide highly 
effective and innovative approaches for treatment of circulatory shock.
As reviewed above, melanocortin peptides of the ACTH/MSH family exert a prompt and 
sustained resuscitating effect in conditions of circulatory shock. This effect is adrenal‑independent 
and occurs through inhibition of the systemic inflammatory response.31,34,75,76,93 Previous investiga‑
tions on the anti‑inflammatory effects of melanocortins showed that systemic administration of 
a‑MSH reduces blood concentrations of IL‑1a and TNF‑a in a mouse model of lipopolysac‑
charide‑induced systemic inflammation.100 Furthermore, Lipton and coworkers showed that in a 
mouse model of peritonitis/endotoxemia induced by cecal ligation and puncture, systemic treat‑
ment with a‑MSH improves survival.101 Collectively, these findings indicate that melanocortins 
counteract the systemic inflammatory response in circulatory shock.
The next question was whether hemorrhagic shock reversal produced by melanocortins 
depends on activation of the vagus nerve‑mediated cholinergic anti‑inflammatory pathway.31 
Action potential recordings in hemorrhage‑shocked rats treated with nanomolar concentrations 
of ACTH‑(1‑24), indicate that neural efferent activity along the vagus nerve markedly increases. 
This effect is associated with the restoration of cardiovascular and respiratory functions, blunted 
NF‑kB activity and decreased TNF‑a in liver and plasma. Bilateral cervical vagotomy, or pharma‑
cological blockade of brain melanocortin MC4 receptors and muscarinic acetylcholine receptors, 
or of peripheral nicotinic acetylcholine receptors, prevents the life‑saving effect of ACTH‑(1‑24) 
and the associated effects on NF‑kB activity and TNF‑a levels.31 Blockade of brain MC4 recep‑
tors and muscarinic receptors (a) blunts the stimulating effect of ACTH‑(1‑24) on efferent vagal 
activity, (b) reduces, like bilateral cervical vagotomy, the blood volume to be withdrawn in order 
to induce shock and (c) prevents the compensatory increase in efferent vagal activity normally 
occurring during bleeding in control shocked animals.31
Collectively, these findings indicate that melanocortins suppress the NF‑kB‑dependent systemic 
inflammatory response triggered by hemorrhage and reverse shock condition, through activation of 
the cholinergic anti‑inflammatory pathway within the brain (Fig. 1). These results likewise indicate 
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that blockade of either brain MC4 receptors, or brain muscarinic receptors, or efferent vagal transmis‑
sion, accelerates the evolution of shock. These observations suggest the existence of a melanocort‑
in‑dependent antishock pathway. The involvement of brain muscarinic receptors in activation of the 
cholinergic anti‑inflammatory pathway has been subsequently confirmed in experimental endotoxic 
shock.102 Blockade of the cholinergic anti‑inflammatory pathway activity by the nicotinic acetylcholine 
receptor antagonist chlorisondamine provides a mechanism for the original observations by Guarini 
and coworkers,66,67 that dimethylphenylpiperazinium and surprisingly nicotine (a CNS acting drug) 
reverse hemorrhagic shock through a peripheral, nicotinic receptor‑mediated pathway.
Interestingly, melanocortins exert their well‑known anti‑inflammatory activity mainly via a 
central mechanism that leads to reduced pro‑inflammatory cytokines and chemokines production 
and increased release of the anti‑inflammatory cytokine IL‑10.11 This mechanism partly overlaps 
with the cholinergic anti‑inflammatory pathway, which modulates the systemic inflammatory 
response in shock conditions by inhibiting monocyte production and release of pro‑inflammatory 
cytokines, but not of the anti‑inflammatory cytokine IL‑10.51
Figure 1. Modulation of the inflammatory response in circulatory shock, through the cholinergic 
anti‑inflammatory pathway. Low levels of inflammatory molecules produced in damaged tissues 
activate afferent signals through ascending vagus nerve fibers (sensory arm of the inflammatory 
reflex). Activation of the cholinergic anti‑inflammatory pathway (motor arm of the inflamma‑
tory reflex, that is impaired during shock) by electrical stimulation of efferent vagal fibers, or 
by stimulation of brain melanocortin MC4 receptors (likely in the vagus dorsal motor nucleus: 
DMN), rapidly leads to acetylcholine (Ach) release in organs of the reticuloendothelial system 
(RES). Acetylcholine released from efferent vagal terminals interacts with a7 subunit‑containing 
nicotinic acetylcholine receptors (a7nAchR) on tissue macrophages and other immune cells sur‑
rounding the cholinergic terminals and inhibits the synthesis/release of inflammatory cytokines, 
with consequent reduction in cytokine plasma levels and attenuation of the systemic inflamma‑
tory response. Acetylcholine interaction with peripheral muscarinic receptors (mAchR) does not 
play a role in circulatory shock. On the contrary, brain muscarinic receptors also are involved 
in triggering the cholinergic anti‑inflammatory pathway.
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Protective Effect of Melanocortins in Myocardial  
Ischemia/Reperfusion
Melanocortins are also highly effective in treatment of animal models of myocardial ischemia. 
Ischemia rapidly causes profound biochemical and morphological changes and induces an inflam‑
matory reaction in the heart tissue. Reperfusion is associated with severe alterations of cellular 
metabolism that may lead to further tissue injury. Myocardial reperfusion causes severe arrhythmias, 
endothelial dysfunction, myocardial stunning, cell death either by necrosis or apoptosis and a high 
lethality.36,103,104 It appears that myocardial ischemia triggers apoptosis and reperfusion accelerates 
the process.105 Both ischemia and reperfusion induce oxidative and nitrosative stress36,106‑108 as well 
as early activation of mitogen‑activated protein kinases and NF‑kB109,110 in cardiac myocytes. These 
signal transduction mechanisms may in part contribute to cardiac injury, by causing early increase 
in expression of heart damaging factors and in part to cardioprotection.111 A number of innovative 
pharmacological approaches to myocardial ischemia/reperfusion injury have been investigated, 
but the results are either conflicting or not confirmed in clinical trials.105,112‑114
We have shown that melanocortins, including [Nle4,d‑Phe7]a‑MSH (NDP‑a‑MSH), g1‑MSH 
and g2‑MSH, injected intravenously during experimental coronary occlusion, exert a protective effect 
both in rats subjected to transient myocardial ischemia followed by reperfusion—an animal model 
characterized by high incidence of ventricular tachycardia (VT), ventricular fibrillation (VF) and 
death—and in rats subjected to permanent coronary artery occlusion.36,37,39,115 Myocardial ischemia/
reperfusion injury also activates the anti‑apoptotic, pro‑survival cascades of the phosphatidylinosi‑
tol 3‑kinase‑Akt and extracellular signal‑regulated kinases (ERK 1/2), that appear to make up an 
universal pro‑survival signalling pathway mediating myocardial protection at reperfusion.111 In the 
rat model of myocardial ischemia/reperfusion described above, ACTH‑(1‑24) enhanced ERK 1/2 
activation, triggering therefore the pro‑survival cascade. In addition, melanocortins reduced histo‑
logical alterations in the left ventricle, including those involving structural proteins, counteracted 
the inflammatory response and stimulated anti‑apoptotic reactions.40
The cardioprotective effect of melanocortins has been confirmed in rat hearts isolated 12 hours 
after treatment with a‑MSH or ACTH‑(4‑10) and then subjected to a 30‑min period of ischemia 
followed by 120 min of reperfusion.41,116 In this experimental model, melanocortin treatment results 
in a reduction in VF, infarct size and activity of the apoptotic protein caspase‑3 and in an increase 
in the expression of the anti‑inflammatory protein heme oxygenase‑1. Melanocortins have also 
been shown to be effective in mouse models of myocardial ischemia/reperfusion.12,38
The prevention of ventricular arrhythmias in transient myocardial ischemia and the reduction 
of infarct size in permanent ischemia may be due to the melanocortin ability to inhibit the oxygen 
free radical discharge and to reduce the inflammatory and apoptotic responses.12,36,39,40 Indeed, 
melanocortin peptides have a peculiar, adrenal‑independent, anti‑inflammatory activity.7,11,21 An 
anti‑apoptotic activity, has also been demonstrated.5,22,45
It appears that the cardioprotective effect of melanocortins could be mediated by brain melano‑
cortin MC3 receptors.36,37,39,40,115 Indeed, when the selective MC3 agonist g2‑MSH was administered 
intracerebroventricularly, a dose ten times lower than that needed by the intravenous route provided 
full protection. This observation could explain the reason why treatment of isolated rat hearts with 
ACTH‑(4‑10) given at the time of reperfusion, rather than “in vivo” before heart harvest, failed 
to improve the post‑ischemic recovery.116 However, the data of Getting and coworkers38 suggest a 
minor participation of cardiac MC3 receptors.
Interestingly, melanocortins also cause a significant increase in allograft survival in experi‑
mental heart transplantation. Although they do not eventually prevent rejection, treatment was 
associated with a marked decrease in leukocyte infiltration and in expression of inflammatory 
molecules involved in allograft rejection.50 Gene expression profile studies have revealed that 
melanocortin treatment of recipients preserves transplanted heart function by altering multiple 
protective pathways.117
Thus, melanocortins could be an useful tool for the prevention of cardiac damage, in different 
conditions of ischemia/reperfusion injury.
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Melanocortins Prevent Myocardial Ischemia/Reperfusion‑Induced 
Damage through Activation of the Cholinergic Anti‑Inflammatory 
Pathway
Electrical stimulation of the vagus nerve has been proposed as a novel approach for treatment 
of myocardial ischemia/reperfusion injury. Indeed, stimulation of the vagus nerve prevented VF 
and VT in cats after myocardial reperfusion following a 20‑min period of coronary occlusion118 
and VF in dogs with a healed myocardial infarction.119 Moreover, it has been reported that vagus 
stimulation improves long‑term survival after chronic heart failure in rats.120 These investigations 
have provided a robust framework for the interpretation of findings by Cheng and coworkers.121
The nucleus ambiguus has long been considered the major vagal nucleus controlling the heart 
activity, whereas the vagus dorsal motor nucleus was thought to play only a marginal role. Recently, 
Cheng and colleagues121 provided anatomical evidence for dual vagal cardiac efferent pathways 
in rats, that could play different roles in control of heart function. The data showed that neurons 
of the nucleus ambiguus and dorsal motor nucleus of the vagus project axons that converge to 
the same cardiac ganglia and innervate separate nonoverlapping populations of principal neurons 
within each cardiac ganglion. These findings, together with functional observations by the same 
investigators,122,123 suggest that both brain nuclei play important, though different, roles in control‑
ling cardiac function. During myocardial ischemia and reperfusion, therefore, one of these dual 
vagal cardiac efferent pathways could be a cholinergic anti‑inflammatory pathway, involved in 
cardioprotection, as it occurs in circulatory shock. Indeed, in conditions of heart failure, a systemic 
inflammatory response plays a fundamental pathogenetic role.124
These observations encouraged further investigations, aimed at determining whether melano‑
cortin peptides activate such vagal efferent pathway(s) in experimental conditions of ischemic heart 
disease. In rats subjected to coronary artery occlusion (5 min) followed by reperfusion (5 min), 
electrical stimulation of efferent vagal fibers (5 V, 2 ms, 1‑9 Hz, for the whole period of ischemia/
reperfusion) has been shown to strongly reduce the incidence of severe arrhythmias and lethality 
and the increases in free radical blood levels and left ventricle histological alterations and to aug‑
ment the activation of the anti‑apoptotic prosurvival kinase ERK 1/2.40 Nanomolar amounts of 
the melanocortins ACTH‑(1‑24) (agonist at all MC receptors) and g2‑MSH (selective agonist 
at MC3 receptors)—administered in rats during coronary occlusion, intravenously or intracere‑
broventricularly at a dose 10 times lower—produces the same protective effects of efferent vagal 
fiber electrical stimulation (Fig. 2).40 Since bilateral cervical vagotomy blunts the beneficial effect 
of ACTH‑(1‑24) and of the selective MC3 agonist g2‑MSH, the protective effect of melanocortins 
likely involves such vagal pathway. Accordingly, blockade of peripheral muscarinic acetylcholine 
receptors prevents the effects of both electrical stimulation and melanocortins; in the latter case, 
also central muscarinic receptors seem to be involved.40
More recently, the improvement in functional recovery, following vagus nerve electrical stimu‑
lation of isolated rat hearts subjected to ischemia/reperfusion injury, has been associated with 
inhibition of cardiomyocyte adenosine triphosphate depletion; indeed, it is established that rapid 
depletion of adenosine triphosphate leads cells to death. In the same investigation, the beneficial 
effect of acetylcholine against depletion of adenosine triphosphate has been also shown in isolated 
cardiomyocytes subjected to hypoxia/reoxygenation. In both studies, the protective effects seem 
to be mediated by muscarinic acetylcholine receptors.125
Overall, these results indicate a protective, efferent vagal cholinergic pathway operative in 
conditions of ischemic heart disease, that could be activated by melanocortins (Fig. 2). The 
melanococortin‑induced activation of such a pathway seems to be triggered by stimulation of brain 
MC3 receptors,37,40,115 with involvement of brain and (as main final step) heart muscarinic receptors. 
Ischemia/reperfusion injury is still considered a major problem in patients with acute coronary 
occlusion and in patients undergoing surgical operations, such as coronary artery bypass grafting. 
These patients could benefit by a pharmacological activation of the cholinergic anti‑inflammatory 
pathway. Benefits for patients with ischemic heart diseases by melanocortin‑induced triggering 
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of the cholinergic anti‑inflammatory pathway could be even greater, because of the established 
ability of melanocortins to increase the anti‑inflammatory cytokine IL‑10 production.11 Indeed, 
modulation of inflammation with IL‑10 attenuates left ventricle disfunction and remodeling after 
acute myocardial infarction in mice.126
Neuroprotection by Melanocortins in Ischemic Stroke
Stroke is the third main cause of death and the leading cause of adult disability in developed 
countries. Within minutes to days after a cerebral vessel occlusion, several pathological pathways are 
triggered, which may potentially damage brain cells.25,127 Despite intensive investigations aimed at 
developing innovative neuroprotective treatments for brain injury, no novel drugs have established 
clinical effectiveness. Toxic side effects, short therapeutic treatment window, single‑mechanism of 
neuronal damage blockade are the main problems.127‑129 Indeed, information from clinical trials 
Figure 2. Modulation of the inflammatory response in myocardial ischemia/reperfusion and 
heart failure, through the cholinergic anti‑inflammatory pathway. Low levels of inflammatory 
molecules produced in damaged tissues activate afferent signals through ascending vagus nerve 
fibers (sensory arm of the inflammatory reflex). Activation of the cholinergic anti‑inflammatory 
pathway (motor arm of the inflammatory reflex, that is impaired during ischemia/reperfusion) 
by electrical stimulation of efferent vagal fibers, or by stimulation of brain melanocortin MC3 
receptors likely located in the vagus dorsal motor nucleus (DMN) or nucleus ambiguous (NA), 
rapidly leads to acetylcholine (Ach) release in the heart. Acetylcholine released from effer‑
ent vagal terminals interacts with muscarinic acetylcholine receptors (mAchR) on myocardial 
tissue leading to cardioprotection. Likely, acetylcholine interaction with peripheral nicotinic 
receptors (a7nAchR) in organs of the reticuloendothelial system (RES) plays a role in myocar‑
dial ischemia/reperfusion and heart failure, a condition where also a systemic inflammatory 
response can occur. Brain muscarinic receptors are also involved in triggering the cholinergic 
anti‑inflammatory pathway.
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suggests that targeting an array of key pathophysiological mechanisms is essential for an effective 
and safe management of stroke.25,127,128,130 At present, the only approved therapy for ischemic stroke 
is thrombolysis within 3 hours of symptom onset.25,128,131 However, only 3% of all stroke patients 
can receive thrombolytic agents, only few of treated patients experience some benefits and a grow‑
ing body of evidence indicates that these drugs also have deleterious effects.25,132
Protective properties of melanocortins in experimental brain ischemia have been reported by 
Lipton’s group. These experiments showed that a‑MSH improves recovery of auditory‑evoked 
potentials in a dog model of transient brain stem ischemia.133 Tatro’s group reported that a‑MSH 
reduces brain TNF‑a levels in transient global and focal cerebral ischemia in mice.134 Recently, 
our research group provided the first clear evidence that melanocortins afford a strong neuro‑
protection against damage consequent to global or focal cerebral ischemia in gerbils and rats, 
through the activation of CNS melanocortin MC4 receptors.45‑47,49 Eleven‑day intraperitoneal 
treatment with nanomolar amounts of the melanocortin NDP‑a‑MSH, but not of the selective 
MC3 receptor agonist g2‑MSH, protects against impairment in learning and memory caused by 
transient global brain ischemia in gerbils (induced by occlusion of the common carotid arteries 
for 10 min).45,46 This protective and long‑lasting (67 days, at least) effect, which is prevented by 
pharmacological blockade of MC4 receptors, occurs also when treatment starts several hours 
after ischemia (being 18 hours the approximate time‑limit). In transient global brain ischemia 
in gerbils, functional recovery after stroke is associated with a modulation of the excitotoxic, 
inflammatory and apoptotic responses in the hippocampus and with a consequent reduction of 
the morphological damage and an increase in the number of viable neurons. The same melano‑
cortin treatment given for 11 days also protects against impairment in learning and memory, 
sensory‑motor orientation and coordinated limb use in a rat model of focal cerebral ischemia 
caused by intrastriatal microinjection of endothelin‑1.47 In this severe experimental model, the 
MC4 receptor‑dependent protective effect of NDP‑a‑MSH is associated with diminished exci‑
totoxic, inflammatory and apoptotic reactions.49 Other beneficial features involve a significant 
reduction of the severe morphological damage of the nucleus striatum, including a reduction of 
neuronal death, demyelination and phagocytic activity. Neuroprotection is also associated with 
a significant increase in number of small vessels within ischemic areas, relative to saline‑treated 
rats. Of great importance, also in these rat studies NDP‑a‑MSH showed a broad therapeutic 
treatment window.47 Subsequently, Forslin Aronsson and coworkers135 and Chen and coworkers48 
confirmed the neuroprotective effect of a‑MSH in other models of global and focal cerebral 
ischemia, without investigating MC receptors.
In conclusion, melanocortin agonists at MC4 receptors appear to produce effective neuroprotec‑
tion with a broad time window and through counteraction of the main ischemia‑related mecha‑
nisms of brain damage. Furthermore, the antipyretic action of melanocortins is well established136 
and hypothermia might contribute to neuroprotection during cerebral ischemia.137 Stroke therapy 
with these neuropeptides, therefore, could take a further advantage by melanocortin‑induced 
hypothermia.25 No novel drug has so far been shown to possess so many favourable and promising 
characteristics, at least in experimental stroke models.
Melanocortins Produce Neuroprotection Against Ischemic Stroke 
by Activating the Cholinergic Anti‑Inflammatory Pathway
Observations in animals138,139 and humans140,141 indicate that stroke is associated with systemic 
pathophysiological reactions. Widespread production/activation of inflammatory mediators in the 
peripheral immune system following focal cerebral ischemia has been reported in mice.142
The systemic pathophysiological reactions associated with focal cerebral ischemia and a 
possible protective involvement of the cholinergic anti‑inflammatory pathway, have been inves‑
tigated in rats.49 Following intrastriatal microinjection of endothelin‑1, the activation of ERK 
1/2, c‑jun N‑terminal kinases and caspase‑3, the increase in TNF‑a concentration and DNA 
fragmentation, as well as the increase in TNF‑a plasma levels, occur over the ensuing hours in 
the striatum and liver of control stroke rats. This suggests cerebral and systemic activation of 
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excitotoxic, inflammatory and apoptotic responses. Intraperitoneal treatment with nanomolar 
doses of NDP‑a‑MSH 3 to 9 hours after stroke suppresses the excitotoxic, inflammatory and 
apoptotic cascades at central and peripheral level. Bilateral vagotomy and pharmacological 
blockade of peripheral nicotinic acetylcholine receptors blunt the neuroprotective effect of 
NDP‑a‑MSH.49 Focal brain ischemia causes, therefore, detrimental effects not only in the brain, 
but also in the liver. This leads to hypothesize that a protective, melanocortin‑activated, vagal 
cholinergic pathway is likely operative in conditions of ischemic stroke, to modulate cerebral 
and systemic pathological reactions (Fig. 3). Decreased expression and impaired function of 
brain muscarinic acetylcholine receptors have been associated with neuron degeneration after 
Figure 3. Modulation of the inflammatory response in ischemic stroke, through the cholinergic 
anti‑inflammatory pathway. Low levels of both brain inflammatory molecules spreading outside 
the blood‑brain barrier and inflammatory molecules produced in damaged peripheral tissues, 
activate afferent signals through ascending vagus nerve fibers (sensory arm of the inflammatory 
reflex). Brain melanocortin MC4 receptor agonists, besides to produce strong neuroprotection 
in the injured brain area, activate the cholinergic anti‑inflammatory pathway (motor arm of the 
inflammatory reflex, that is impaired after stroke), likely by acting on MC4 receptors in the vagus 
dorsal motor nucleus (DMN), leading to acetylcholine (Ach) release in organs of the reticuloen‑
dothelial system (RES). Acetylcholine released from efferent vagal terminals interacts with a7 
subunit‑containing nicotinic acetylcholine receptors (a7nAchR) on tissue macrophages and 
other immune cells surrounding the cholinergic terminals and inhibits the synthesis/release of 
inflammatory cytokines, with a consequent reduction in cytokine plasma levels and the attenu‑
ation of the systemic inflammatory response. Protective signals towards the CNS via the afferent 
vagal fibers (owing to the activation of the vagus nerve‑mediated cholinergic anti‑inflammatory 
pathway) also seem to occur in stroke. It is unknown whether acetylcholine interaction with 
peripheral muscarinic receptors (mAchR) plays a role in ischemic stroke. Likely, brain muscarinic 
receptors are also involved in triggering the cholinergic anti‑inflammatory pathway. Electrical 
stimulation has not been assessed in stroke models.
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ischemic stroke.143 This suggests that brain muscarinic receptors may be involved in triggering the 
cholinergic anti‑inflammatory pathway much as in circulatoy shock and myocardial ischemia.
However, the vagus nerve‑mediated cholinergic anti‑inflammatory pathway is an efferent 
pathway and its activation by melanocortins can only account for the peripheral protective ef‑
fects observed by Ottani and coworkers.49 How can we explain why vagotomy and peripheral 
nicotinic receptor blockade blunt the protective effect of melanocortins against brain damage? 
It has been reported that lipopolysaccharide‑induced systemic inflammation in conjunction 
with global cerebral ischemia exacerbates brain damage in rats.144 This suggests that inhibition 
of systemic responses could result in cerebral protective effects. Moreover, vagal afferents are 
widely distributed throughout the CNS and vagus nerve stimulation causes synaptic activation 
at multiple sites in both cerebral hemispheres.55 Therefore, protective signals towards the CNS 
owing to the activation of the vagus nerve‑mediated cholinergic anti‑inflammatory pathway can 
be hypothesized in stroke (Fig. 3).
Evidence suggests that in conditions of brain ischemia endogenous melanocortins could exert 
a role in neuroprotection. A) Melanocortin‑treated stroke animals learn more rapidly than sham 
ischemic ones,45,46 but after the blockade of melanocortin MC4 receptors there is a worsening in 
memory recovery, as compared with ischemic control animals.45,46 B) Melanocortins increase the 
anti‑inflammatory cytokine IL‑10 that modulates the inflammatory cascade.11,21 Interestingly, it 
has been reported that low plasma concentrations of IL‑10 are associated with early worsening of 
neurological symptoms in stroke patients.145 C) a‑MSH concentrations in plasma are reduced in 
patients with acute traumatic brain injury. Consistent with a physiological neuroprotective role of 
melanocortins, patients with the lowest circulating levels have an unfavourable outcome.11
Taken together, these observations point to a neuroprotective role of a cholinergic anti‑in‑
flammatory pathway, likely activated by melanocortins, that could be physiologically operative 
in conditions of ischemic stroke and brain injury, to protect against local and systemic damage. 
This further supports the important role of the cholinergic anti‑inflammatory pathway in the 
defense mechanisms.
Conclusion
MC3 and MC4 receptors are the most abundant MC receptor subtypes within the CNS, being 
brain distribution of MC4 receptors broader than that of MC3.5,7,11,21 MC3 and MC4 receptors also 
occur in the vagus dorsal motor nucleus and ventral division of the nucleus ambiguous19,146 and these 
receptors are believed to play an important role in central regulation of certain body functions.5,147 
This supports the hypothesis that central melanocortins activate efferent vagal fiber‑mediated 
cholinergic anti‑inflammatory pathway(s) to protect against damage caused by circulatory shock, 
myocardial ischemia and ischemic stroke and perhaps following other severe inflammatory insults. 
Such efferent cholinergic pathways could be specific for different pathological conditions; indeed, 
in circulatory shock and ischemic stroke this pathway seems to be mediated by peripheral nicotinic 
acetylcholine receptors, whereas in myocardial ischemia peripheral muscarinic acetylcholine recep‑
tors appear to be predominantly involved. However, because MC receptors, including MC3 and 
MC4, are also expressed in numerous peripheral tissues,7,11,15,21 additional protective influences of 
melanocortins likely occur via interactions with peripheral melanocortin receptors.
The CNS and peripheral organs communicate via neuronal and humoral pathways.52,53 After 
brain injury, immunodepression and inflammation in peripheral organs can occur. Indeed, several 
cerebral injury types have been shown to be associated with intestinal, pulmonary and hepatic in‑
flammation.5 The abundant distribution of MC3 and MC4 receptors within the CNS, together with 
the preclinically demonstrated ability of melanocortins acting at central MC3 and MC4 receptors 
to prevent central and peripheral detrimental consequences of a brain inflammatory injury due to 
ischemia and reperfusion, suggest promising perspectives for the clinical use of melanocortins. These 
brain receptors could be pharmacological targets for the treatment of several central and peripheral 
disorders, likely through the activation of the efferent vagal anti‑inflammatory pathway(s).31,40,49
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Several instances of ischemia/reperfusion injuries could take advantage of melanocortin‑in‑
duced activation of the cholinergic anti‑inflammatory pathway, also because melanocortins 
increase the production and release of the potent anti‑inflammatory cytokine IL‑10 from mono‑
cytes through a b2‑adrenergic receptor‑dependent mechanism.11,52 Indeed, it is well established 
that melanocortins also stimulate adrenergic transmission and therefore they can centrally 
modulate local and systemic inflammation through both adrenergic and cholinergic pathways.5,11 
Recent data suggest that the splenic nerve, through a complex mechanism involving adrenergic 
and cholinergic signals, is required for the cholinergic anti‑inflammatory pathway activity against 
systemic inflammation and the spleen could be a primary source of TNF‑a.70,148
Investigations designed at determining the molecular mechanisms of the cholinergic anti‑in‑
flammatory pathway activation could provide further insight into the neural regulation of inflam‑
mation and could help design of superselective activators of such a pathway: agonists at individual 
brain MC receptors could be significant candidates.
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